Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression
May 19 2020 - 9:01AM
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, today
announced that it will host a key opinion leader (KOL) call to
discuss the unmet medical needs in suicide and depression on
Tuesday, May 26, 2020 at 1:00 p.m. Eastern Time.
The call will feature a discussion with Distinguished University
Health Professor Emeritus at the University of South Florida
College of Medicine, David V. Sheehan, MD, MBA. Dr. Sheehan will
discuss the unmet medical needs in treating suicidal patients with
depression and other mental health conditions. Dr. Sheehan will be
available to answer questions at the conclusion of this call.
Raj Mehra, Ph.D., Chairman and CEO of Seelos Therapeutics, Inc.,
will discuss Seelos’ lead candidate, Intranasal Racemic Ketamine
(SLS-002) for Acute Suicidal Ideation and Behavior (ASIB) in
patients with Major Depressive Disorder (MDD).
This call will be moderated by Mario Nacinovich, MSc, a member
of the adjunct faculty at Boston University. Mr. Nacinovich is the
founding editor of the Journal of Communication in Healthcare. He
is currently a show host on Reach MD and recently launched an
additional program on NRN, "Stealth on Health".
Dial-in and Webcast Information |
Domestic: |
877-407-0789 |
International: |
201-689-8562 |
Conference
ID: |
13704179 |
Webcast: |
Click Here
For Webcast |
David V. Sheehan, M.D., M.B.A. is Distinguished University
Health Professor Emeritus at the University of South Florida
College of Medicine. He was Professor of Psychiatry, Director of
Psychiatric Research and Director of the Depression and Anxiety
Disorders Research Institute at the University of South Florida
College of Medicine and Professor of Psychology at the University
of South Florida College of Arts and Sciences. He completed his
residency training in psychiatry at Massachusetts General Hospital
and Harvard Medical School. At Harvard Medical School, where he was
Assistant Professor of Psychiatry, he was on the full-time faculty
for 12 1/2 years. He was the Director of Anxiety Research and
Director of the Psychosomatic Medicine Clinic at Massachusetts
General Hospital. He received his MBA (summa cum laude) from the
University of South Florida. He served as Director of Psychiatric
Research for the Department of Psychiatry and Behavioral Medicine
at the University of South Florida College of Medicine from
1985-2007. He has written over 550 abstracts and 300 publications
including a bestseller The Anxiety Disease (which sold over half a
million copies). He has been awarded over $20 million for 130
research grants. He was awarded two patents by the United States
Patent Office in 1996 and 2015. He has given expert testimony to
the Unites States Congress. He was elected as a member of the
American College of Psychiatrists and is a Distinguished Life
Fellow of the American Psychiatric Association and is a Charter
Member of the National Academy of Inventors. Among other honors, he
has been included in “The Best Doctors in America” published by
Woodward/White Inc. every year from 1992 until his retirement in
2010.
About Seelos Therapeutics:Seelos Therapeutics,
Inc. is a clinical-stage biopharmaceutical company focused on the
development and advancement of novel therapeutics to address unmet
medical needs for the benefit of patients with central nervous
system (CNS) disorders and other rare diseases. The Company's
robust portfolio includes several late-stage clinical assets
targeting indications including Acute Suicidal Ideation and
Behavior (ASIB) in Major Depressive Disorder (MDD) or
Post-Traumatic Stress Disorder (PTSD), Sanfilippo syndrome,
Parkinson’s Disease, other psychiatric and movement disorders plus
orphan diseases.
For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Contact Information:Anthony MarcianoHead of
Corporate CommunicationsSeelos Therapeutics, Inc. (SEEL)300 Park
Ave., 12th FlNew York, NY 10022(646)
293-2136anthony.marciano@seelostx.comhttps://seelostherapeutics.com/https://twitter.com/seelostxhttps://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seelos Therapeutics (NASDAQ:SEEL)
Historical Stock Chart
From Apr 2023 to Apr 2024